- Design
- Retrospective registry cohort with propensity matching (SEER)
- Population
- 16,322 patients with pT1b-2 N0M0 renal cell carcinoma treated with nephrectomy
- Primary outcome
- Cancer-specific mortality
- Effect
- 5-year CSM 7.6% vs 5.9%; about 1.3-fold higher (P = 0.02) with delay over 3 months
This study used the US SEER database (2004 to 2021) to identify 16,322 patients with pT1b-2 N0M0 renal cell carcinoma treated with partial or radical nephrectomy. It compared surgery more than three months after diagnosis (18% of patients) with surgery within three months, using propensity matching and competing-risks analysis.
After matching, five-year cancer-specific mortality was 7.6% with surgery after three months and 5.9% within three months; delay was independently associated with about 1.3 times the risk (P = 0.02). The association grew with longer delay: about 1.3-fold at three to six months and 1.6-fold beyond six months. It held across grades but not in non-clear cell tumours.
Small renal masses under 4 cm are often safely observed, but these are larger tumours. In Indian public hospitals, where surgical waiting lists can stretch for months, these data argue for prioritising pT1b and larger clear cell tumours. SEER data cannot capture why surgery was delayed, so frailty, workup or patient choice may confound the link.
- Consider a target of surgery within three months of diagnosis for clinical T1b-T2 renal masses.
- Prioritise larger clear cell tumours on waiting lists over small or indolent masses.
- Record the reason for any delay beyond three months in the notes.
- Consider active surveillance mainly for small renal masses, not for T1b-T2 tumours fit for surgery.
Why it matters
The safety of watchful waiting for small masses does not carry over to larger kidney tumours.
Don't overread it
Registry data cannot show why surgery was delayed, so unmeasured factors may explain part of the association.
The statistics, in plain English
A 1.7 percentage-point difference in five-year cancer death corresponds to about one extra cancer death for every 60 patients with delayed surgery, if the association were causal. The dose-response pattern strengthens the case that timing matters, though it does not prove it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free